Clinical Management: Oncology Flashcards
7 cards from real CSP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Clinical Management: Oncology flashcards as text
A patient on erlotinib develops a grade 2 acneiform rash on the face and chest. What is the most appropriate management?
Answer: Oral doxycycline or minocycline plus topical corticosteroid while continuing therapy
Tetracycline antibiotics with low-potency topical steroids manage EGFR inhibitor rash, which often correlates with response.
A patient on pembrolizumab has grade 3 immune-mediated hepatitis. What is the recommended action?
Answer: Hold pembrolizumab and start systemic corticosteroids such as methylprednisolone 1-2 mg/kg/day
Grade 3 hepatitis requires holding the checkpoint inhibitor and high-dose corticosteroids, with infliximab avoided due to hepatotoxicity.
A patient on nivolumab develops asymptomatic hypothyroidism with elevated TSH. What is the most appropriate management?
Answer: Continue nivolumab and start levothyroxine replacement
Immune-related hypothyroidism is managed with hormone replacement, and immunotherapy can usually continue.
Which monitoring is required for patients receiving trastuzumab?
Answer: Baseline and periodic LVEF assessment (e.g., every 3 months)
Trastuzumab can cause cardiomyopathy, so LVEF is assessed at baseline and periodically during treatment.
A patient develops diarrhea 3 days after irinotecan. What is the recommended initial loperamide regimen?
Answer: 4 mg at onset, then 2 mg every 2 hours until diarrhea-free for 12 hours
Late-onset irinotecan diarrhea requires aggressive high-dose loperamide to prevent dehydration.
Which antiemetic regimen is recommended for highly emetogenic chemotherapy such as cisplatin?
Answer: NK1 antagonist, 5-HT3 antagonist, dexamethasone, and olanzapine
Guidelines recommend a four-drug regimen for highly emetogenic chemotherapy to prevent acute and delayed CINV.
Rasburicase is contraindicated in which patient being treated for tumor lysis syndrome risk?
Answer: Patient with G6PD deficiency
Rasburicase generates hydrogen peroxide, which can cause hemolysis and methemoglobinemia in G6PD deficiency.